Clinical Trial Update: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of oral palbociclib (PD-0332991) as a single agent or with letrozole for first-line ER-positive, HER2-negative advanced breast cancer in Japanese …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Letrozole (letrozole)
• Palbociclib (palbociclib)

Snippet

Sponsor: Pfizer | Conditions: Neoplasms, Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2017-05-02